Overview
Guideline & Testing Update for Treatment of Invasive Fungal Infections in Hospitalized Patients
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
The incidence of invasive fungal infections continues to increase, resulting in significant morbidity and mortality, despite the introduction of expanded treatment options. Clinicians require up-to-date knowledge of advances in testing approaches and novel antifungal agents to guide clinician-decision making and ensure that at-risk patients receive prompt, appropriate therapy.
This educational activity is designed for infectious disease specialists, intensivists, hospitalists, hospital pharmacists, and other clinicians involved in the management of patients with invasive fungal infections.
The incidence of invasive fungal infections continues to increase, resulting in significant morbidity and mortality, despite the introduction of expanded treatment options. Clinicians require up-to-date knowledge of advances in testing approaches and novel antifungal agents to guide clinician-decision making and ensure that at-risk patients receive prompt, appropriate therapy.
Upon completion of this activity, participants will be able to:
- Identify patients at risk of invasive fungal infections in critical care and other hospital settings
- Compare and contrast the mechanisms of action, pharmacokinetics, efficacy, and safety of available and emerging antifungal agents
- Apply diagnostic and susceptibility testing for invasive fungal infections to ensure prompt, appropriate antifungal therapy
- Implement strategies to enhance empiric and definitive antifungal therapy for candidemia
Sponsored by The Academy for Continued Healthcare Learning
Supported by an educational grant from Astellas Scientific & Medical Affairs, Inc.
Craig A. Martin, PharmD, BCBS
Clinical Associate Professor, Adjunct
Director of Professional Practice Development
UK College of Pharmacy and UK Healthcare
Lexington, Kentucky
Peter G. Pappas, MD
Professor of Medicine
Director, Mycoses Study Group
Division of Infectious Diseases
Department of Medicine
University of Alabama at Birmingham
Birmingham, Alabama
Clinical Associate Professor, Adjunct
Director of Professional Practice Development
UK College of Pharmacy and UK Healthcare
Lexington, Kentucky
Peter G. Pappas, MD
Professor of Medicine
Director, Mycoses Study Group
Division of Infectious Diseases
Department of Medicine
University of Alabama at Birmingham
Birmingham, Alabama
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME/CE activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME/CE activity. ACHL also requires participating faculty to disclose when unapproved/unlabeled uses of a product are discussed in a CME/CE activity.
Craig A. Martin, PharmD, BCBS, Type of financial relationship:
Research Grant: Pfizer
Discussion of Off-Label, Investigational, or Experimental Drug Use: Ravuconazole and isavuconazole
Peter G. Pappas, MD, Type of financial relationships:
Grants Recipient/Advisory Board: Astellas Scientific & Medical Affairs, Inc., Merck & Co, Inc., Gilead Sciences, and T2 Biosystems, Inc.
Discussion of Off-Label, Investigational, or Experimental Drug Use: Ravuconazole and isavuconazole
Craig A. Martin, PharmD, BCBS, Type of financial relationship:
Research Grant: Pfizer
Discussion of Off-Label, Investigational, or Experimental Drug Use: Ravuconazole and isavuconazole
Peter G. Pappas, MD, Type of financial relationships:
Grants Recipient/Advisory Board: Astellas Scientific & Medical Affairs, Inc., Merck & Co, Inc., Gilead Sciences, and T2 Biosystems, Inc.
Discussion of Off-Label, Investigational, or Experimental Drug Use: Ravuconazole and isavuconazole
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Essential Areas and Elements, Updated Criteria, Policies, and Standards for Commercial Support, as well as the ACPE Accreditation Standards for Continuing Pharmacy Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This educational activity was planned and produced in accordance with the ACCME Essential Areas and Elements, Updated Criteria, Policies, and Standards for Commercial Support, as well as the ACPE Accreditation Standards for Continuing Pharmacy Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
The participant should complete the preactivity survey, view the webcast, and complete the post-test and evaluation forms. To receive credit, 80% must be achieved on the post-test. A certificate of credit will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
Hardware and Software Requirements |
An active Internet connection (DSL or Cable). A wireless, dial-up, or slow connection may have constant buffering problems. Windows
Mac OS
|
The Academy for Continued Healthcare Learning (ACHL) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. |
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
| |
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. | |
This activity has been approved for a maximum of 1.25 Contact Hours. ACPE Universal Activity Number (UAN): 0396-0000-13-129-L01-P Activity Type(s): Knowledge Note that CPE credit will be submitted to NABP on the first day of each month. |